NEW YORK, NY--(Marketwire - October 25, 2011) -
Daxor Corporation (NYSE Amex: DXR
), a medical instrumentation and biotechnology company, today announced the filing of a patent for an automated instrument to measure total body albumin. Albumin is the major carrier molecule in the human body. It functions as a transfer molecule for hundreds of different molecules and is effectively a parallel circulation within the body. Albumin I131 is the tracer used by the BVA-100 Blood Volume Analyzer for measuring total blood volume.
Albumin is a key molecule in maintaining effective blood pressure within the body. There are many conditions such as kidney failure, heart failure and liver failure, diabetes where albumin is lost to the circulation and may have decreased production in the liver. When albumin levels drop, there may be a serious disruption in the ability of the circulating blood to retain plasma within the circulation. This may result in swelling of a patient's extremities, accumulation of fluid in the abdomen, and most serious of all, transudation of fluid in the lungs known as pulmonary edema. Pulmonary edema is a major complication in heart failure patients.
At the present time the standard test for determining albumin is to measure the concentration in the blood plasma. This measurement, however, does not tell you the total amount of albumin in a patient's body. Daxor has worked on a method to measure the total amount of body albumin for approximately five years. Daxor attorneys filed for a patent on the first accurate automated method to measure the total amount of albumin in the human body. The test will require measurement of the total amount of blood in an individual. Precise results will be available within 24 hours of the quantity of the albumin in an individual's body.
Albumin circulates at approximately 1/400 at the rate at which blood circulates. The albumin transudates out of the capillary system and is eventually recycled via the lymphatic system back into the blood stream. Albumin is greatly underutilized in the treatment of many medical and surgical problems because physicians have been unable to evaluate the total amount of albumin in the human body. The ability to actually quantify on an accurate basis the total amount of albumin in the human body could be expected to increase the utilization of this substance. Albumin also has the capability of expanding a patient's blood volume and has sometimes been used to support situations where blood pressure has collapsed, where transfusions are not immediately available.
The company will begin Beta testing in 2012. The company expects to be filing two additional patents in the near future. One of these patents relates to a new improved blood volume analyzer and another patent relates to a collection system for collecting multiple blood samples from a patient utilizing a method that requires only a single veni puncture instead of multiple needle sticks.
The inventors of the total body albumin analyzer are Dr. Joseph Feldschuh and the co-inventor is Jonathan Feldschuh, who is the oldest son of Dr. Feldschuh. The patents have been assigned to the Daxor Corporation. Jonathan Feldschuh was the co-inventor of the original blood volume analyzer, the BVA-100. He is a Suma Cum Laude graduate in Physics from Harvard, works as an artist as well as a financial consultant for the Aristark Hedge Fund which trades Japanese securities. Jonathan provides no financial analysis services to Daxor and Daxor has provided no financial services to Aristark and does not trade Japanese securities.
For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com or Contact Dr. Joseph Feldscuh, at 212-244-0804, or Diane Meegan, Investor Relations, 212-330-8512, email@example.com.